EDAP TMS SA Secures French Reimbursement Approval for Focal One Robotic HIFU Prostate Cancer Treatment

Reuters

09/08

EDAP TMS SA Secures French Reimbursement Approval for Focal One Robotic HIFU Prostate <a href="https://laohu8.com/S/CTHZ">Cancer Treatment</a>

Edap TMS SA, a global leader in robotic energy-based therapies, announced on September 8, 2025, that the French Ministry of Health has granted reimbursement for the High Intensity Focused Ultrasound (HIFU) procedure for prostate cancer treatment in France. This approval covers the use of the Focal One Robotic HIFU procedure under France's national universal health system, "Sécurité Sociale," for eligible patients as a primary treatment for localized prostate cancer and as a salvage treatment following radiotherapy. This reimbursement milestone, effective from September 1, 2025, enhances patient access to non-invasive prostate cancer management in France. The decision follows the positive findings of the HIFI Study, sponsored by the French Urology Association, and is expected to facilitate similar approvals across Europe.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edap TMS SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001126766-en) on September 08, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2565683115"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2565683115\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2565683115?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-08 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2565683115","market":"us","top_or_hot":-1,"title":"EDAP TMS SA Secures French Reimbursement Approval for Focal One Robotic HIFU Prostate Cancer Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      EDAP TMS SA Secures French Reimbursement Approval for Focal One Robotic HIFU Prostate <a href=\"https://laohu8.com/S/CTHZ\">Cancer Treatment</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Edap TMS SA, a global leader in robotic energy-based therapies, announced on September 8, 2025, that the French Ministry of Health has granted reimbursement for the High Intensity Focused Ultrasound (HIFU) procedure for prostate cancer treatment in France. This approval covers the use of the Focal One Robotic HIFU procedure under France's national universal health system, \"Sécurité Sociale,\" for eligible patients as a primary treatment for localized prostate cancer and as a salvage treatment following radiotherapy. This reimbursement milestone, effective from September 1, 2025, enhances patient access to non-invasive prostate cancer management in France. The decision follows the positive findings of the HIFI Study, sponsored by the French Urology Association, and is expected to facilitate similar approvals across Europe.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edap TMS SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001126766-en) on September 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EDAP TMS SA Secures French Reimbursement Approval for Focal One Robotic HIFU Prostate Cancer Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEDAP TMS SA Secures French Reimbursement Approval for Focal One Robotic HIFU Prostate Cancer Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-08 19:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      EDAP TMS SA Secures French Reimbursement Approval for Focal One Robotic HIFU Prostate <a href=\"https://laohu8.com/S/CTHZ\">Cancer Treatment</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Edap TMS SA, a global leader in robotic energy-based therapies, announced on September 8, 2025, that the French Ministry of Health has granted reimbursement for the High Intensity Focused Ultrasound (HIFU) procedure for prostate cancer treatment in France. This approval covers the use of the Focal One Robotic HIFU procedure under France's national universal health system, \"Sécurité Sociale,\" for eligible patients as a primary treatment for localized prostate cancer and as a salvage treatment following radiotherapy. This reimbursement milestone, effective from September 1, 2025, enhances patient access to non-invasive prostate cancer management in France. The decision follows the positive findings of the HIFI Study, sponsored by the French Urology Association, and is expected to facilitate similar approvals across Europe.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edap TMS SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001126766-en) on September 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nNDL4pc3Nw:1","article_id":"2565683115","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2565683115","pubTimestamp":1757329296,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Edap TMS SA, a global leader in robotic energy-based therapies, announced on September 8, 2025, that the French Ministry of Health has granted reimbursement for the High Intensity Focused Ultrasound  procedure for prostate cancer treatment in France. This approval covers the use of the Focal One Robotic HIFU procedure under France's national universal health system, \"Sécurité Sociale,\" for eligible patients as a primary treatment for localized prostate cancer and as a salvage treatment following radiotherapy. This reimbursement milestone, effective from September 1, 2025, enhances patient access to non-invasive prostate cancer management in France. The decision follows the positive findings of the HIFI Study, sponsored by the French Urology Association, and is expected to facilitate similar approvals across Europe.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4588":"碎股","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4082":"医疗保健设备","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","NDAQ":"纳斯达克OMX交易所","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","EDAP":"Edap Tms SA"},"translate_title":"EDAP TMS SA获得法国报销批准Focal One机器人HIFU前列腺癌治疗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EDAP":0.9,"NDAQ":0.9},"content_text":"EDAP TMS SA Secures French Reimbursement Approval for Focal One Robotic HIFU Prostate Cancer Treatment\n\n\n        Edap TMS SA, a global leader in robotic energy-based therapies, announced on September 8, 2025, that the French Ministry of Health has granted reimbursement for the High Intensity Focused Ultrasound (HIFU) procedure for prostate cancer treatment in France. This approval covers the use of the Focal One Robotic HIFU procedure under France's national universal health system, \"Sécurité Sociale,\" for eligible patients as a primary treatment for localized prostate cancer and as a salvage treatment following radiotherapy. This reimbursement milestone, effective from September 1, 2025, enhances patient access to non-invasive prostate cancer management in France. The decision follows the positive findings of the HIFI Study, sponsored by the French Urology Association, and is expected to facilitate similar approvals across Europe.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edap TMS SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001126766-en) on September 08, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}